Stay updated with breaking news from Guilan university. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Study Setting In Ethiopia, by the time this study was conducted, there were 47 Ethiopian Public Universities (EPU) distributed in all regions of the country. Of these 47 EPU, only 30 of them were selected for this study with the criteria of having had Midwifery Education Program (MEP) and had started teaching midwifery clinical courses. Specifically, these 30 EPU are three (Adigrat, Aksum, and Mekelle) universities from the Tigray region; Seven (Bahir Dar, Debre Birhan, Debre Markos, and Debre Tabor, Gondar, Woldiya, and Wollo) universities from Amhara region; Eight (Ambo, Arsi, Bulehora, Haramaya, Jimma, Madawalabu, Metu, and Wollega) universities from Oromia region; seven (Arba Minch, Dilla, Hawassa, Mizan-Tepi, Wachamo, Welkite, and Wolayita Sodo) universities from South Nation, Nationalities and Peoples region; and the rest five are as follows: Addis Ababa University found in Addis Ababa federal city administration which is the capital city of the country; Dire Dawa Univer ....
Article content TOKYO A study of global trials of Fujifilm Holdings Corp’s antiviral drug Avigan suggests it has little benefit for COVID-19 patients once their symptoms become serious. The meta-analysis of nine clinical trials showed the drug, known generically as favipiravir, helped patients early on in their hospitalization, according to the preprint of a study posted Wednesday on the medical website medRxiv. We apologize, but this video has failed to load. Try refreshing your browser, or Fujifilm s Avigan shows no significant benefit on COVID-19 mortality - study Back to video But it failed to demonstrate statistically significant results in reducing mortality among those with mild to moderate COVID-19. ....
Fujifilm s Avigan shows no significant benefit on COVID-19 mortality: study Reuters 18/02/2021 TOKYO (Reuters) - A study of global trials of Fujifilm Holdings Corp s antiviral drug Avigan suggests it has little benefit for COVID-19 patients once their symptoms become serious. The meta-analysis of nine clinical trials showed the drug, known generically as favipiravir, helped patients early on in their hospitalisation, according to the preprint of a study posted Wednesday on the medical website medRxiv. But it failed to demonstrate statistically significant results in reducing mortality among those with mild to moderate COVID-19. We should consider that perhaps the use of antivirals once the patient has symptoms is too late and this would explain their low efficacy in the clinical setting, wrote the authors, led by Soheil Hassanipoura of Iran s Guilan University of Medical Sciences. ....
Fujifilm's Avigan shows no significant benefit on COVID-19 mortality: study reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
E-Mail An analysis of the first wave of the epidemic in Iran in 8902 people suggests the overall proportion of people with SARS-CoV-2 antibodies in their blood - known as seroprevalence - may be higher than rates based on clinical cases alone, at around 17.1% seropositivity vs 0.6% based on modelling from previous studies, by end of April 2020. However, seroprevalence varies widely between cities - with the highest estimates found in Rasht (72.6%) and the lowest in Sanandaj (1.7%) although some cities had small samples sizes. Despite high seroprevalence in a few cities, a large proportion of population is still uninfected. The potential shortcomings of current public health policies should therefore be identified to prevent future epidemic waves in Iran. ....